NEW YORK (360Dx) – Bio-Rad Laboratories said on Tuesday that it has entered into an agreement that gives it commercialization rights to Visia Imaging's second-generation immunofluorescence slide processing and reading platform for the evaluation of autoimmune diseases.

Laboratories frequently employ immunofluorescence slides as a first step in screening for numerous autoimmune diseases, including systemic lupus erythematosus, Bio-Rad said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.